Kura Oncology

Ziftomenib Clin1 AML, 10 efforts Clin0 AML, ALL; KO-2806 3 efforts RD/Clin0 multiple cancers

Kura Oncology is using precision oncology to find cures for cancer patients. By understanding the evolving molecular processes that drive cancer, Kura is pioneering new approaches to treat diseases, including head and neck cancer, lung cancer and acute leukemias. In particular, Kura is gaining a deep understanding of the underlying causes of treatment resistance - this will enable them to design smart combination regimens with other cancer therapies to target tumors from multiple directions, improving the likelihood of success. Important to their approach, Kura is finding novel biomarkers that can be used to stratify patients through the use of precision oncology. Kura’s lead candidate, ziftomenib, is a small molecule drug that is currently being investigated in clinical trials.